Chemoprevention of intestinal polyposis in the ApcΔ716mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor

Cancer Research

Volumn 61, Issue 4, 2001, Pages 1733-1740

  Oshima, Masanobu ^a   Murai Hata, Naomi ^a   Kargman, Stacia ^b   Arguello, Meztli ^b   Luk, Pauline ^b   Kwong, Elizabeth ^b   Taketo, Makoto M ^c   Evans, Jilly F ^d  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^c UNIVERSITY OF TOKYO   (Japan)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DRUG METABOLITE; ROFECOXIB; SULINDAC;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; COLON CANCER; CONTROLLED STUDY; DNA REPLICATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GASTROINTESTINAL POLYPOSIS; INTESTINE CANCER; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANIMALS; ANTICARCINOGENIC AGENTS; BETA CATENIN; CELL NUCLEUS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOSKELETAL PROTEINS; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENES, APC; INTESTINAL NEOPLASMS; INTESTINAL POLYPS; ISOENZYMES; LACTONES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES; SULINDAC; TRANS-ACTIVATORS;

EID: 0035866401     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Aspirin and the potential role of prostaglandins in colon cancer
2. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
3. Cyclooxygenase in biology disease
4. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues
5. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent
6. Sulindac suppresses tumorigenesis in the Min mouse
7. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
8. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
9. Structure of the mitogen-inducible T1S10 gene and demonstration that the T1S10-encoded protein is a functional prostaglandin G/H synthase
10. Human cyclooxygenase-2 cDNA
11. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
12. New insights into the mode of action of antiinflammatory drugs
13. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain
14. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor
15. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib)
16. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo-controlled pilot study of rofecoxib
17. Rofecoxib, a specific inhibitor of cyclooxygenase-2, with clinical efficacy comparable with that of diclofenac sodium
18. Preliminary study of the safety and efficacy of SC-58635. A novel cyclooxygenase-2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis and studies of gastrointestinal and platelet effects
19. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
20. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
21. The relationship between cyclooxygenase-2 expression and colorectal cancer
22. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas
23. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
24. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
25. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
26. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
27. Modulation of apoptosis by prostaglandin treatment in human colon cancer cells
28. Molecular pathology of cyclooxygenase-2 in neoplasia
29. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene
30. Δ716knockout mice by inhibition of cyclooxygenase 2 (COX-2)
31. The specific cyclooxygenase-2 inhibitor, celecoxib, causes adenoma regression in the Apc mutant Min mouse
32. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
33. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells
34. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective orally active COX-2 inhibitor
35. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
36. Single and multiple dose pharmacokinetics (PK) of rofecoxib (R) in healthy subjects
37. Absorption of sulindac from a novel (Pro-Sorb™) liquid formulation
38. Δ716knockout mice
39. Essential histidines of prostaglandin endoperoxide synthase
40. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis
41. Phase 1 trial of Exsulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis
42. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
43. Host cyclooxygenase-2 modulates carcinoma growth
44. Dynamics of cadherin/catenin complex formation: Novel protein interactions and pathways of complex assembly
45. β-catenin expression in primary and metastatic colorectal carcinoma
46. Cyclooxygenase-2 is up-regulated and localized to macrophages in the intestine of Min mice
47. 2by tissue-fixed macrophages in colonic carcinoma
48. Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis
49. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas and selective toxicity against Apc mutant embryos
50. Preferential enhancement of tumor radio-response by a cyclooxygenase-2 inhibitor
51. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines